Glp-1

Eli Lilly Direct-To-Consumer Push Shouldn't Worry Distributors: JPMorgan

Eli Lilly Stock Tumbles As Kennedy Targets Weight Loss Drugs

Novo Nordisk Q3 Preview: Will $285 Million Weight Loss Bet Offset Bearish Charts?

Eli Lilly Stock Tumbles As Kennedy Targets Weight Loss Drugs

Novo Nordisk Q3 Preview: Will $285 Million Weight Loss Bet Offset Bearish Charts?

Hims & Hers Health Stock Is Tumbling Thursday: Here's Why

Viking Therapeutics Stock Could Soar 45% Ahead Of Key Weight Loss Drug Readout: JPMorgan

Hims & Hers Health Stock Is Tumbling Thursday: Here's Why

Viking Therapeutics Stock Could Soar 45% Ahead Of Key Weight Loss Drug Readout: JPMorgan

EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'

EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO

Glp-1 Recent News

Will Novo Nordisk Building Fires Serve As A Catalyst For Eli Lilly? Redditors See A Stock Split For US Company 'Very Likely'

Eli Lilly's stock may rise due to supply issues at competitor Novo Nordisk, according to Reddit users. Its weight loss drug and upcoming FDA approval are also factors. Investors are optimistic about its future performance.

New Weight Loss ETF Is Essentially A Play On Eli Lilly, Novo Nordisk

New OZEM ETF offers investors exposure to weight-loss sector through top pharmaceutical companies Eli Lilly and Novo Nordisk, with potential for high growth but also risks.

EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic

Roundhill CEO Dave Mazza says investors "can't just buy a basket of big pharma names or a broad-based biotech ETF and call it a day."

Top 7 Biotech Stock Winners As Weight Loss Drug Battle Escalates: Goldman Sachs Names Best Picks

Goldman Sachs analysts identified a substantial opportunity in the manufacturing sector for new obesity therapeutics, as demand for these treatments escalates.

Gary Black Keeping Tabs On Oprah's Upcoming TV Special About Ozempic — 'Shame, Blame And The Weight Loss Revolution'

Future Fund co-founder Gary Black shared details about Oprah Winfrey's upcoming TV special discussing her weight loss journey and the use of GLP-1 weight loss drugs, potentially impacting stocks of Novo Nordisk and Eli Lilly, major players in the market.

S&P 500 Sets Sights On 5,400, But Analyst Warns Of Imminent Market Volatility

Bank of America's equity strategist Savita Subramanian has raised the S&P 500 year-end target to 5,400, signaling a 5% upside potential.

;